AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04284995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RUC-4 Compound
Description: All patients will receive a single subcutaneous dose of RUC-4 in the Cardiac Catheterization Lab (CCL) before coronary angiography/percutaneous coronary intervention.
Study NCT01622686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PictureRx medication label
Description: Reformatted medication labels that adhere to current best practices for label design and also include illustrations
Study NCT04751539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 single dose
Description: AND017 administrated as oral single-dose on Day 1 in Part A
Study NCT04751539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AND017 multiple dose
Description: AND017 administrated once daily from Day 1 to Day 10 in Part B
Study NCT04751539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administrated once on Day 1 in Part A or daily from Day 1 to Day 10 in Part B
Study NCT03761680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MEDPass mode of administration
Description: Allocation of 50 ml of ONS four times per day distributed with the medication rounds
Study NCT03761680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Patients receive ONS between meals or at their request as usual
Study NCT02543619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injection technique
Description: One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
Study NCT03349008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Entecavir
Description: Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
Study NCT03349008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Glycyrrhizin for the treatment of patients with chronic hepatitis B combined with entecavir-based
Study NCT03349008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Isoglycyrrhizinate
Description: Magnesium Isoglycyrrhizinate Injection treat for two weeks with entecavir-based
Study NCT03349008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diammonium Glycyrrhizinate
Description: Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
Study NCT03349008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Isoglycyrrhizinate Placebo
Description: Magnesium Isoglycyrrhizinate Injection Placebo
Study NCT03349008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diammonium Glycyrrhizinate Placebo
Description: Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
Study NCT03958123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 μg cebranopadol
Description: Encapsulated 100 μg cebranopadol tablet.
Study NCT03958123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 μg cebranopadol
Description: Encapsulated 200 μg cebranopadol tablet.
Study NCT03958123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 μg cebranopadol
Description: Encapsulated 400 μg cebranopadol tablet.
Study NCT03958123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to cebranopadol encapsulated tablets
Description: Matching placebo to cebranopadol encapsulated tablet.
Study NCT03481816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061; adenoviral MUC1 vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
Study NCT03481816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051; adenoviral brachyury vaccine
Description: 5 x 10 to the eleventh power VP (standard dose), 1 x 10 to the eleventh power VP (DL-1), or 5 x 10 to the tenth power VP (DL-2) subcutaneous injection every 3 weeks for 3 immunizations.
Study NCT03958123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg Moxifloxacin
Description: Encapsulated 400 mg moxifloxacin tablet.
Study NCT03958123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to moxifloxacin encapsulated tablets
Description: Matching placebo to moxifloxacin (400 mg) encapsulated tablet.
Study NCT03934320 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FAMCAT
Description: The intervention is a computer-based software algorithm (FAMCAT) for use in general practice with a family history questionnaire.
Study NCT01688570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
Study NCT01688570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyproheptadine
Description: Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
Study NCT01688570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
Study NCT00475592 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Capsule Endoscopy
Study NCT00475592 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Upper Gastrointestinal Endoscopy
Study NCT03497273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: Itacitinib administered orally once daily at the protocol-defined dose.
Study NCT03497273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid
Description: Either oral prednisolone or intravenous methylprednisolone at the investigator's discretion.
Study NCT00769353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary and Secondary Coping Enhancement Training
Description: A cognitive behavioral therapy designed to help individuals cope with physical illness.
Study NCT00769353 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Non-directive Therapy
Description: A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
Study NCT04135885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: The patient was continuously taking 7 ml of a brown sugar aqueous solution containing a certain amount of folic acid for 7 days before surgery (0.3 mg/d for children with 1-3 years old and 0.4 mg/d for children aged 4 to 5, once a day). After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
Study NCT04135885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Patients in the placebo group received 20 ml of an aqueous solution of brown sugar with the same concentration as the intervention group on the 7th day before surgery. After the operation, the PAED scores were performed every 10 minutes during the recovery of the child, at the time of extubation, and within 30 minutes after extubation. The PAED scores of all the children were performed by the same measurer. (The total score is 0\~20 points, and the score ≥10 points is defined as the recovery period).
Study NCT02730871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension
Study NCT02730871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brinzolamide/brimonidine vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT02730871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/timolol 0.5% solution
Description: 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
Study NCT02730871 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Travoprost 0.004%/timolol 0.5% solution
Description: 1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
Study NCT02703558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenazopyridine
Study NCT02703558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescein
Study NCT03197116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone reminder
Description: Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
Study NCT03197116 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No other
Description: No additional reminder will be offered
Study NCT04570592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron 1 Mg/mL Intravenous Solution And Dexamethasone 4mg
Description: Comparing PONV incidences in both arms
Study NCT04570592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Granisetron 1 Mg/mL Intravenous Solution
Description: Comparing PONV incidences in both arms
Study NCT00823472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mild stimulation
Description: Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
Study NCT01646749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Differences in protein content (En%) of meals
Description: The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
Study NCT00766649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
Study NCT00996749 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO
Study NCT02131246 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
Study NCT00996749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone scan
Description: Correlative studies
Study NCT00996749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dual x-ray absorptometry
Description: Correlative studies
Study NCT00996749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00996749 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT00391196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive placebo plus non-pharmacological weight loss program.
Study NCT00391196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Study NCT00391196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598 Treatment B
Description: Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Study NCT02918656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infographic presentation of health information
Description: The students in this group will read Cochrane systematic review summary in infographics format.~Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs.
Study NCT02918656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLS presentation of health information
Description: The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
Study NCT02918656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scientific abstract presentation of health information
Description: The students in scientific abstract group will read the the text written for the academic population and practitioners.
Study NCT04019444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd155-RG
Description: The ChAd155-RG Vaccine consists of a replication-defective group C ChAd, ChAd155, expressing RG under the control of the CMV promoter. The RG sequence cloned into the ChAd155 vector is a medoid, a natural viral strain with the highest average percent of amino acid identity among all RG sequences annotated in the NCBI database. The selected RG (NCBI strain AGN94271) shares an average 94% percent identity to the RGs in current vaccines.
Study NCT04019444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.
Study NCT04019444 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 0.9% Sodium Chloride, USP injection.
Study NCT04019444 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: The RABAVERT Vaccine is an inactivated, purified chick embryo cell vaccine (PCECV). It consists of lyophilized rabies virus (strain Flury LEP) that has been propagated in chicken fibroblasts, inactivated with beta-propiolactone, and concentrated and purified by centrifugation
Study NCT02840526 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral blockade (PVB)
Description: preoperative ThPVB performed unilaterally at Th10 level
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sopodorm
Description: midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sopodorm
Description: midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol WZF
Description: propofol 2 mgkg-1intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol WZF
Description: propofol 2 mgkg-1intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nimbex
Description: cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimbex
Description: cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl WZF
Description: fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl WZF
Description: fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevorane
Description: sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevorane
Description: sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
Study NCT02840526 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation
Description: Intratracheal intubation with a single lumen endotracheal tube
Study NCT03633656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model Predictive Control of Iron Dosing
Description: Model Predictive Control of Iron Dosing
Study NCT01876420 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The CoreValve™ Evolut R TAV™ system
Description: CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 \& 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
Study NCT00687466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.~Glargine should be administered once daily in the morning and always at the same hour.
Study NCT02840526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Intratracheal intubation with a single lumen endotracheal tube
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxynorm
Description: 1 mgml-1 concentration oxycodone solution intravenously
Study NCT01941875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Effervescent Vaginal Tablets
Description: Experimental
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxynorm
Description: 1 mgml-1 concentration oxycodone solution intravenously
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paracetamol Kabi
Description: 1g paracetamol intravenously every 6 hours
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol Kabi
Description: 1g paracetamol intravenously every 6 hours
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketonal
Description: 100 mg ketoprofen intravenously every 12 hours
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketonal
Description: 100 mg ketoprofen intravenously every 12 hours
Study NCT02840526 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine WZF
Description: 0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
Study NCT02707939 — intervention group
Intervention type: OTHER
Intervention: Observation
Description: Patients will be observed before and after they receive anesthesia
Study NCT02996955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social support
Description: behaviour change intervention
Study NCT02996955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: treatment of illness perceptions
Description: educational interview
Study NCT02996955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment of illness perceptions
Description: educational interview
Study NCT02099708 — intervention group
Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
Study NCT02996955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activ8
Description: wearing a move monitor
Study NCT02996955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activ8
Description: wearing a move monitor
Study NCT02996955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: activity advice
Description: walking or cycling 5 days a week during at least half an hour
Study NCT02996955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: activity advice
Description: walking or cycling 5 days a week during at least half an hour
Study NCT03514888 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: 40mg of Mitomycin-C dissolved in 100ml normal saline will be added into the perfusate and instilled into the patient for a total of 60 minutes. After 60 minutes, the abdomen will be irrigated with 3 liters of normal saline.
Study NCT02322099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate
Description: alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
Study NCT02322099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
Study NCT02322099 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium carbonate and colecalciferol
Description: Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation